Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry

Čihorić, Nikola; Tsikkinis, Alexandros; Rhoon, Gerard C. van; Crezee, J.; Aebersold, Daniel M.; Bodis, Stephan; Beck, Marcus; Nadobny, Jacek; Budach, Volker; Wust, Peter; Ghadjar, Pirus

doi:10.3109/02656736.2015.1040471

Cited by 181 publications

(126 citation statements)

References 36 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Mild temperature hyperthermia (HT) in the range between [41][42][43][44][45] C is applied as a radiosensitiser in combination with radiotherapy (RT) with excellent clinical results [1,2]. Treatment planning is essential to optimise the radiation dose and temperature delivered to the tumour while minimising the risk of normal tissue complications.…”

Section: Introductionmentioning

confidence: 99%

Thermoradiotherapy planning: Integration in routine clinical practice

Crezee

Leeuwen

Oei

et al. 2015

International Journal of Hyperthermia

Self Cite

View full text Add to dashboard Cite

Planning of combined radiotherapy and hyperthermia treatments should be performed taking the synergistic action between the two modalities into account. This work evaluates the available experimental data on cytotoxicity of combined radiotherapy and hyperthermia treatment and the requirements for integration of hyperthermia and radiotherapy treatment planning into a single planning platform. The underlying synergistic mechanisms of hyperthermia include inhibiting DNA repair, selective killing of radioresistant hypoxic tumour tissue and increased radiosensitivity by enhanced tissue perfusion. Each of these mechanisms displays different dose-effect relations, different optimal time intervals and different optimal sequences between radiotherapy and hyperthermia. Radiosensitisation can be modelled using the linear-quadratic (LQ) model to account for DNA repair inhibition by hyperthermia. In a recent study, an LQ model-based thermoradiotherapy planning (TRTP) system was used to demonstrate that dose escalation by hyperthermia is equivalent to $10 Gy for prostate cancer patients treated with radiotherapy. The first step for more reliable TRTP is further expansion of the data set of LQ parameters for normally oxygenated normal and tumour tissue valid over the temperature range used clinically and for the relevant time intervals between radiotherapy and hyperthermia. The next step is to model the effect of hyperthermia in hypoxic tumour cells including the physiological response to hyperthermia and the resulting reoxygenation. Thermoradiotherapy planning is feasible and a necessity for an optimal clinical application of hyperthermia combined with radiotherapy in individual patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Thermoradiotherapy planning: Integration in routine clinical practice

Crezee

Leeuwen

Oei

et al. 2015

International Journal of Hyperthermia

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, there were many reviews about hyperthermia randomized trials and indicated that it can enhance the efficacy of both radiotherapy and chemotherapy, and also many non-and randomized clinical trials have demonstrated the significant improvement in clinical outcome from adding hyperthermia to standard treatment regimens of radiation and/or chemotherapy [26][27][28][29][30][31][32][33][34] . Maluta, et al 37,38) .…”

Section: - -mentioning

confidence: 99%

Thermal Therapy as Multidisciplinary Therapy Applied to Rectal Cancer:

et al. 2017

View full text Add to dashboard Cite

To avoid colostomy, we try to improve local control, i.e. to perform pathological complete response (pCR) by the neoadjuvant chemoradiation (NACR) with concurrent thermal therapy, falling into a so-called "wait-and-see policy". The aim of this study is examined whether the treatment response of NACR with concurrent thermal therapy for rectal cancer can be predicted after the treatment completion and we showed the changing history of our treatment protocol, current results of our study and a new perspective and potential role of thermal therapeutic approaches in patients with rectal cancer. In this study, 81 patients with rectal cancers (54 resected, M:F＝61:20, median age 63 years old (33-89), from December 2011 to May 2015) were received intensity-modulated radiotherapy (IMRT) (total dose 50 Gy/25 fractions) with capecitabine (1,700 mg/m 2 / day) for five weeks. Thermal therapy was performed using the Thermotron-RF 8, once a week for 5 weeks with 50 min irradiation. Clinical complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were shown in 33.4%, 38.3%, 12.3%, and 16.0% of the patients, respectively. Patients with a gross tumor volume (GTV) ≤ 32 cm 3 and a radiofrequency (RF) output difference (RO difference) ≥ 0 Watt/min exhibited the rates of pathological complete response (pCR) 42.9% and complete response (CR) 71.4%, and those with RO difference＜0 Watt/min, 23.1% and 92.3%, respectively. While, patients with a GTV ≥ 80 cm 3 and a RO difference ≥ 0 Watt/min exhibited the rates of pCR and CR 23.1% and 30.8%, and those with RO difference＜0 Watt/min, 0% and 0%, respectively. Skin temperature significantly changed in patients with a pathological grade 3 tumor compared both to those who had PD and other outcomes, in the Therapeutic potential of thermal therapy H. Shoji et al. 75- -

show abstract

“…Hyperthermia, defined here as local heating of the tumour to relatively moderate temperatures of [40][41][42][43] C for approximately one hour, is an excellent radiosensitiser and chemosensitiser effective in multiple tumour types [33][34][35][36][37][38][39][40][41]. Clinically, hyperthermia is always combined with either radiotherapy or chemotherapy [35,[42][43][44].…”

Section: Hyperthermiamentioning

confidence: 99%

“…A successful anti-CSC therapy should be characterised by the ability to (i) target cells in areas populated by CSCs which are often difficult to reach by conventional therapies; (ii) destroy or modify the tumour microenvironment that sustains CSCs; (iii) kill cycling and non-cycling cells; and (iv) overcome the efficient DNA repair pathways that protect CSCs' genomes. Here we argue that hyperthermia, defined as local heating of the tumour to [40][41][42][43] C, is one anti-cancer treatment that may fit this challenging bill.…”

Section: Introductionmentioning

confidence: 99%

Targeting therapy-resistant cancer stem cells by hyperthermia

Oei

Vriend

Krawczyk

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

Eradication of all malignant cells is the ultimate but challenging goal of anti-cancer treatment; most traditional clinically-available approaches fail because there are cells in a tumour that either escape therapy or become therapy-resistant. A subpopulation of cancer cells, the cancer stem cells (CSCs), is considered to be of particular significance for tumour initiation, progression and metastasis. CSCs are considered in particular to be therapy-resistant and may drive disease recurrence, which positions CSCs in the focus of anti-cancer research, but successful CSC-targeting therapies are limited. Here, we argue that hyperthermia -a therapeutic approach based on local heating of a tumour -is potentially beneficial for targeting CSCs in solid tumours. First, hyperthermia has been described to target cells in hypoxic and nutrient-deprived tumour areas where CSCs reside and ionising radiation and chemotherapy are least effective. Second, hyperthermia can modify factors that are essential for tumour survival and growth, such as the microenvironment, immune responses, vascularisation and oxygen supply. Third, hyperthermia targets multiple DNA repair pathways, which are generally upregulated in CSCs and protect them from DNA-damaging agents. Addition of hyperthermia to the therapeutic armamentarium of oncologists may thus be a promising strategy to eliminate therapy-escaping and -resistant CSCs.ARTICLE HISTORY

show abstract

Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry

Cited by 181 publications

References 36 publications

Thermoradiotherapy planning: Integration in routine clinical practice

Thermoradiotherapy planning: Integration in routine clinical practice

Thermal Therapy as Multidisciplinary Therapy Applied to Rectal Cancer:

Targeting therapy-resistant cancer stem cells by hyperthermia

Contact Info

Product

Resources

About